科华生物
(002022)
| 流通市值：30.75亿 | | | 总市值：30.76亿 |
| 流通股本：5.14亿 | | | 总股本：5.14亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 787,309,260.67 | 864,626,234.89 | 871,631,162.41 | 1,472,262,633.27 |
| 应收票据及应收账款 | 872,707,704.51 | 877,621,178.02 | 1,077,755,354.68 | 1,122,423,143.26 |
| 其中：应收票据 | 8,299,340.85 | 6,319,069.02 | 368,733.04 | 2,222,980 |
| 应收账款 | 864,408,363.66 | 871,302,109 | 1,077,386,621.64 | 1,120,200,163.26 |
| 应收款项融资 | 11,782,600.48 | 6,595,820.95 | 5,167,650.14 | 21,282,676.74 |
| 预付款项 | 112,420,057.97 | 89,516,194.79 | 160,057,719.52 | 125,689,155.53 |
| 其他应收款合计 | 14,291,136.82 | 15,345,739.65 | 21,238,080.72 | 24,731,859.52 |
| 存货 | 867,320,643.11 | 875,200,497.27 | 1,046,522,791.27 | 1,018,903,608.73 |
| 其他流动资产 | 115,643,981.84 | 107,219,456.7 | 108,905,036.01 | 102,122,509.2 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 2,781,753,895.05 | 2,836,418,713.67 | 3,443,996,206.91 | 4,089,772,747.06 |
| 非流动资产: | | | | |
| 长期应收款 | 28,068,426.83 | 26,938,842.32 | 27,607,886.42 | 26,591,387.13 |
| 长期股权投资 | 3,369,644.69 | 3,504,797.43 | 1,750,000 | - |
| 其他权益工具投资 | 23,393,686 | 23,393,686 | 24,886,900 | 24,886,900 |
| 投资性房地产 | 571,570.54 | 576,015.25 | 580,459.95 | 584,905.19 |
| 固定资产 | 797,268,974.48 | 802,484,780.76 | 853,741,820.28 | 865,256,831.75 |
| 在建工程 | 2,296,398.38 | 3,577,432.37 | 4,143,303.46 | 3,776,520.75 |
| 使用权资产 | 56,634,298.37 | 52,657,617.37 | 50,807,630.1 | 50,526,034.81 |
| 无形资产 | 370,977,474.45 | 382,804,313.7 | 414,264,806.86 | 393,676,047.35 |
| 开发支出 | 165,832,028.2 | 151,161,325.35 | 136,714,287.25 | 151,854,778.62 |
| 商誉 | 665,941,345.97 | 660,295,559.04 | 694,307,033.83 | 690,362,472.22 |
| 长期待摊费用 | 49,366,275.92 | 41,598,881.85 | 40,222,186.96 | 40,567,966.97 |
| 递延所得税资产 | 234,816,825.44 | 232,628,293.88 | 239,842,769.26 | 239,092,750.28 |
| 其他非流动资产 | 15,417,750.83 | 18,087,793.85 | 7,732,036.31 | 7,007,534.86 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 2,413,954,700.1 | 2,399,709,339.17 | 2,496,601,120.68 | 2,494,184,129.93 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 5,195,708,595.15 | 5,236,128,052.84 | 5,940,597,327.59 | 6,583,956,876.99 |
| 流动负债: | | | | |
| 短期借款 | 141,412,523.73 | 83,422,498.53 | 37,312,876.96 | 63,059,386.31 |
| 应付票据及应付账款 | 299,710,367.72 | 276,236,208.23 | 336,668,231.59 | 350,354,925.59 |
| 其中：应付票据 | 5,150,419.2 | 6,504,316.8 | 22,509,936.32 | 60,258,760.32 |
| 应付账款 | 294,559,948.52 | 269,731,891.43 | 314,158,295.27 | 290,096,165.27 |
| 合同负债 | 110,470,019.12 | 114,552,836.62 | 79,577,927.7 | 71,285,979.81 |
| 应付职工薪酬 | 53,808,322.28 | 97,354,111.09 | 58,427,472.47 | 53,972,429.12 |
| 应交税费 | 17,930,341.16 | 12,011,202.35 | 24,457,355.73 | 14,092,732.95 |
| 其他应付款合计 | 128,545,702.3 | 168,048,275.7 | 154,661,226.69 | 207,372,079.12 |
| 其中:应付利息 | 2,294,814.44 | 1,453,158.23 | 601,631.9 | 8,215,906.67 |
| 应付股利 | 38,000,000 | 77,697,150 | 82,797,150 | 120,797,150 |
| 一年内到期的非流动负债 | 60,117,340.15 | 59,644,596.74 | 57,665,002.3 | 58,053,884.1 |
| 其他流动负债 | 9,266,996.48 | 8,563,765.22 | 8,542,896.6 | 7,358,694.65 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 821,261,612.94 | 819,833,494.48 | 757,312,990.04 | 825,550,111.65 |
| 非流动负债: | | | | |
| 长期借款 | 80,388,201.53 | 86,444,505.36 | 98,777,546.47 | 94,810,275.61 |
| 应付债券 | 216,301,983.65 | 214,298,130.39 | 212,274,622.2 | 688,123,781.84 |
| 租赁负债 | 30,934,735.06 | 25,942,012.66 | 27,332,053.89 | 27,123,223.95 |
| 预计负债 | 66,685,205.95 | 62,148,575.21 | 45,813,055.51 | 48,054,884.44 |
| 递延收益 | 32,724,503.16 | 34,563,639 | 33,946,527.44 | 35,884,448.9 |
| 递延所得税负债 | 10,009,176.47 | 10,516,973.46 | 18,321,583.6 | 18,403,168.48 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 437,043,805.82 | 433,913,836.08 | 436,465,389.11 | 912,399,783.22 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 1,258,305,418.76 | 1,253,747,330.56 | 1,193,778,379.15 | 1,737,949,894.87 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 514,318,121 | 514,317,589 | 514,317,484 | 514,317,273 |
| 其他权益工具 | 43,512,890.83 | 43,515,016.12 | 43,515,441.18 | 142,426,796.4 |
| 资本公积 | 228,216,954.78 | 228,204,761 | 262,462,860.65 | 193,165,463.13 |
| 减:库存股 | 101,017,583.6 | 101,017,583.6 | 94,231,579.14 | 84,263,100.75 |
| 其他综合收益 | 5,651,212.28 | -6,257,250.18 | 9,328,090.02 | 2,929,225.66 |
| 盈余公积 | 228,578,647.53 | 228,578,647.53 | 228,578,647.53 | 228,578,647.53 |
| 未分配利润 | 2,389,225,439.3 | 2,442,485,224.08 | 2,960,946,443.57 | 3,030,622,997.21 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 3,308,485,682.12 | 3,349,826,403.95 | 3,924,917,387.81 | 4,027,777,302.18 |
| 少数股东权益 | 628,917,494.27 | 632,554,318.33 | 821,901,560.63 | 818,229,679.94 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 3,937,403,176.39 | 3,982,380,722.28 | 4,746,818,948.44 | 4,846,006,982.12 |
| 负债和股东权益合计 | 5,195,708,595.15 | 5,236,128,052.84 | 5,940,597,327.59 | 6,583,956,876.99 |
| 公告日期 | 2025-04-30 | 2025-04-28 | 2024-10-22 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |